Bozó E, Medgyes A, Boros S, Kuszmann J
Institute for Drug Research, Budapest, Hungary.
Carbohydr Res. 2000 Oct 20;329(1):25-40. doi: 10.1016/s0008-6215(00)00156-7.
Two independent approaches were investigated for the synthesis of 3,4-di-O-acetyl-1,6:2,5-dianhydro-1-thio-D-glucitol (18), a key intermediate in the synthesis of 1,3,4-tri-O-acetyl-2,5-anhydro-6-thio-alpha-D-glucoseptanose (13), needed as glycosyl donor. In the first approach 1,6-dibromo-1,6-dideoxy-D-mannitol was used as starting material and was converted via 2,5-anhydro-1,6-dibromo-1,6-dideoxy-4-O-methanesulfonyl-3-O-tetrahydropy ranyl-D-glucitol into 18. The second approach started from 1,2:5,6-di-O-isopropylidene-D-mannitol and the allyl, 4-methoxybenzyl as well as the methoxyethoxymethyl groups were used, respectively, for the protection of the 3,4-OH groups. The resulting intermediates were converted via their 1,2:5,6-dianhydro derivatives into the corresponding 3,4-O-protected 2,5-anhydro-6-bromo-6-deoxy-D-glucitol derivatives. The 1,6-thioanhydro bridge was introduced into these compounds by exchanging the bromine with thioacetate, activating OH-1 by mesylation and treating these esters with sodium methoxide. Among these approaches, the 4-methoxybenzyl protection proved to be the most suitable for a large scale preparation of 18. Pummerer rearrangement of the sulfoxide, obtained via oxidation of 18 gave a 1:9 mixture of 1,3,4-tri-O-acetyl-2,5-anhydro-6-thio-alpha-L-gulo- (12) and -D-glucoseptanose 13. When 12 or 13 were used as donors and trimethylsilyl triflate as promoter for the glycosylation of 4-cyanobenzenethiol, a mixture of 4-cyanophenyl 3,4-di-O-acetyl-2,5-anhydro-1,6-dithio-alpha-L-gulo- (58) and -alpha-D-glucoseptanoside (61) was formed suggesting an isomerisation of the heteroallylic system of the intermediate. A similar mixture of 58 and 61 resulted when 18 was treated with N-chloro succinimide and the mixture of chlorides was used in the presence of zinc oxide for the condensation with 4-cyanobenzenethiol. When 4-nitrobenzenethiol was applied as aglycon and boron trifluoride etherate as promoter, a mixture of 4-nitrophenyl 3,4-di-O-acetyl-2,5-anhydro-1,6-dithio-alpha-L-gulo- (60) and -alpha-D-glucoseptanoside (62) was obtained. Deacetylation of 58, 61 and 62 according to Zemplen afforded 4-cyanophenyl 2,5-anhydro-1,6-dithio-alpha-L-glucoseptanoside (59), 4-cyanophenyl 2,5-anhydro-1,6-dithio-alpha-D-glucoseptanoside (63) and 4-nitrophenyl 2,5-anhydro-1,6-dithio-alpha-D-glucoseptanoside (66), respectively. The 4-cyano group of 63 was transformed into the 4-aminothiocarbonyl, and the 4-(methylthio)(imino)methyl derivative and the 4-nitro group of 66 into the acetamido derivative. All of these thioglycosides displayed a stronger oral antithrombotic effect in rats compared with beciparcil, used as reference.
研究了两种独立的方法来合成3,4 - 二 - O - 乙酰基 - 1,6:2,5 - 脱水 - 1 - 硫代 - D - 葡萄糖醇(18),它是合成1,3,4 - 三 - O - 乙酰基 - 2,5 - 脱水 - 6 - 硫代 - α - D - 葡萄糖七糖(13)所需的关键中间体,13用作糖基供体。在第一种方法中,1,6 - 二溴 - 1,6 - 二脱氧 - D - 甘露醇用作起始原料,并通过2,5 - 脱水 - 1,6 - 二溴 - 1,6 - 二脱氧 - 4 - O - 甲磺酰基 - 3 - O - 四氢吡喃基 - D - 葡萄糖醇转化为18。第二种方法从1,2:5,6 - 二 - O - 异亚丙基 - D - 甘露醇开始,分别使用烯丙基、4 - 甲氧基苄基以及甲氧基乙氧基甲基基团保护3,4 - OH基团。所得中间体通过其1,2:5,6 - 脱水衍生物转化为相应的3,4 - O - 保护的2,5 - 脱水 - 6 - 溴 - 6 - 脱氧 - D - 葡萄糖醇衍生物。通过用硫代乙酸盐交换溴,用甲磺酰化活化OH - 1并用甲醇钠处理这些酯,将1,6 - 硫代脱水桥引入这些化合物中。在这些方法中,4 - 甲氧基苄基保护被证明最适合大规模制备18。通过氧化18得到的亚砜的普默勒重排得到1,3,4 - 三 - O - 乙酰基 - 2,5 - 脱水 - 6 - 硫代 - α - L - 古洛糖 - (12)和 - D - 葡萄糖七糖13的1:9混合物。当将12或13用作供体并使用三氟甲磺酸三甲基硅酯作为4 - 氰基苯硫醇糖基化的促进剂时,形成了4 - 氰基苯基3,4 - 二 - O - 乙酰基 - 2,5 - 脱水 - 1,6 - 二硫代 - α - L - 古洛糖 - (58)和 - α - D - 葡萄糖七糖苷(61)的混合物,这表明中间体的杂烯丙基系统发生了异构化。当用N - 氯代琥珀酰亚胺处理18并在氧化锌存在下将氯化物混合物用于与4 - 氰基苯硫醇缩合时,得到了类似的58和61混合物。当将4 - 硝基苯硫醇用作糖苷配基并使用三氟化硼乙醚作为促进剂时,得到了4 - 硝基苯基3,4 - 二 - O - 乙酰基 - 2,5 - 脱水 - 1,6 - 二硫代 - α - L - 古洛糖 - (60)和 - α - D - 葡萄糖七糖苷(62)的混合物。根据曾普伦方法对58、61和62进行脱乙酰化,分别得到4 - 氰基苯基2,5 - 脱水 - 1,6 - 二硫代 - α - L - 葡萄糖七糖苷(59)、4 - 氰基苯基2,5 - 脱水 - 1,6 - 二硫代 - α - D - 葡萄糖七糖苷(63)和4 - 硝基苯基2,5 - 脱水 - 1,6 - 二硫代 - α - D - 葡萄糖七糖苷(66)。63的4 - 氰基转化为4 - 氨基硫代羰基,66的4 - (甲硫基)(亚氨基)甲基衍生物和4 - 硝基转化为乙酰氨基衍生物。与用作参考的贝西帕西尔相比,所有这些硫代糖苷在大鼠中均表现出更强的口服抗血栓作用。